PROVIZ - a Machine Learning Software, to Support Targeting of Prostate Biopsies on MR Images in Biopsy-naive Patients

Prostate Cancer Diagnosis Clinical Trial

Official title:

A Proof-of-technology, Pilot, Prospective Clinical Study to Investigate the Feasibility and Performance of PROVIZ-a Radiomics-based Machine Learning Software, to Support Targeting of Prostate Biopsies on MRI Images in Biopsy-naive Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06000046
• Other study ID #: 479272
• Secondary ID: CIV-NO-23-04-042
• Status: Recruiting
• Phase: N/A
• Start date: December 20, 2023
• Est. completion date: December 2024

Study information

• Verified date: June 2024
• Source: Norwegian University of Science and Technology
• Contact: Tone Frost Bathen, Prof.
• Phone: +4773551355
• Email: tone.f.bathen[@]ntnu.no
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To perform a traditional feasibility clinical investigation, as defined in ISO 14155:2020, to investigate preliminary feasibility, safety, and clinical performance information of a near-final design of the investigational software. This will be performed through a prospective clinical study on biopsy naïve men with suspected prostate cancer examined with MRI at St. Olavs Hospital, Trondheim, Norway, in order to adequately plan an appropriate pivotal clinical investigation.

Description:

In this prospective study, after referral for suspected prostate cancer, the patient is scanned with magnetic resonance imaging (MRI) in accordance with guidelines of the standardized healthcare pathway. For consenting patients, the images are interpreted in two ways: first, in the conventional manner, i.e., manually by a radiologist, to determine whether clinically significant cancer is suspected. If so, the radiologist will delineate the suspicious lesions. In the second approach, the software will perform the same task as the radiologist, but automatically. If either or both interpretations point to significant cancer, the patient will be sent for targeted biopsy sampling. Histopathologic evaluation of the samples will then determine whether significant cancer is present in each of the targeted lesions (delineated by the radiologist, software, or both). Feasibility is evaluated by measuring the overall failure rate of the software. This is measured by the technical performance log automatically generated by the software, which records all errors and failures during the study. If the record showed an overall failure rate less than 10% across all subjects, the software will be considered feasible. The safety of the software is evaluated by the records of the serious adverse device effects (SADEs) of the software during the study. The software will be considered safe with no occurrence of death or serious injury. The results of the histopathological evaluation will be used to evaluate the performance of the investigational software. This allows comparisons to be made between results obtained with the traditional manual approach alone, with the software alone, and with the manual approach assisted by the software. Statistical analysis will be performed to determine if there are significant differences and if the software adds value.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Biopsy-naive men undergoing MRI examination for suspected prostate cancer via the Norwegian standardized care pathway.
• Patients who give consent to participate during the enrollment period.

Exclusion Criteria:

• Patients who have undergone a biopsy for prostate cancer in the past 3 years.
• Patients who currently enrolled in an active surveillance program for prostate cancer.
• Patients who have had hip replacements that may affect the quality of the image.
• Patients with claustrophobia.
• Patients who intolerance to glucagon or buscopan.
• Patients who unable to sign the informed consent themselves.

Related Conditions & MeSH terms

• Disease
• Prostate Cancer Diagnosis

Intervention

Device:
• Automatic image analysis
After referral for suspected prostate cancer, the patient is scanned with magnetic resonance imaging (MRI) in accordance with guidelines of the standardized healthcare pathway. For consenting patients, the images are interpreted in two ways: first, in the conventional manner, i.e., manually by a radiologist, to determine whether clinically significant cancer is suspected. If so, the radiologist will delineate the suspicious lesions. In the second approach, the software will perform the same task as the radiologist, but automatically. If either or both interpretations point to significant cancer, the patient will be sent for targeted biopsy sampling. Histopathologic evaluation of the samples will then determine whether significant cancer is present in each of the targeted lesions (delineated by the radiologist, software, or both).

Locations

Country	Name	City	State
Norway	St. Olav's University Hospital	Trondheim

Sponsors (2)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology	St. Olavs Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of the software in prospective study in a relevant clinical environment.	The percentage of occurrence of a technical problem in the investigational software that hinders its use is less than 10% across all subjects.	Approximately 45 days. Actual time in clinic is approximately 1.5 hours.
Primary	Safety of the software in prospective study in a relevant clinical environment.	There are no death or serious harm associated with an adverse device effect (ADE) of the investigational software.	Approximately 45 days. Actual time in clinic is approximately 1.5 hours.
Secondary	Performance of the software in prospective study in a relevant clinical environment.	Comparable preliminary detection rate of clinically significant prostate cancer lesions from the software to the radiologist.	Approximately 45 days. Actual time in clinic is approximately 1.5 hours.